Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes

Diabetes Care

Volumn 29, Issue 7, 2006, Pages 1471-1477

  Wagner, Henrik ^a,c   Degerblad, Marie ^a   Thorell, Anders ^b   Nygren, Jonas ^b   Ståhle, Agneta ^a   Kuhl, Jeanette ^a   Brismar, Torkel B ^a   Öhrvik, John ^a   Efendic, Suad ^a   Båvenholm, Peter N ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ERSTA HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; APOLIPOPROTEIN; GLUCOSE; HEMOGLOBIN A1C; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BODY COMPOSITION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; FITNESS; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ACARBOSE; APOLIPOPROTEINS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS;

EID: 33746467589     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc05-2513     Document Type: Article

References (30)

1. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708-723, 2002
2. The DECODE-study group, European Diabetes Epidemiology Group: Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies: Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 42:647-654, 1999
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
4. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ: Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 286:1218-1227, 2001
5. Kelley DE, Goodpaster BH: Effects of exercise on glucose homeostasis in type 2 diabetes mellitus. Med Sci Sports Exerc 33:S495-S501, 2001 (discussion S528-S499)
6. Breuer HW: Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 41:421-440, 2003
7. Laube H, Linn T, Heyen P: The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 106:231-233, 1998
8. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193, 1996
9. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D: Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23:1162-1167, 2000
10. Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Kohler C, Wildbrett J, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M: Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 5:38-44, 2003
11. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB: Effect of lowering post-prandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance. Am J Physiol Endocrinol Metab 287:E906-E911, 2004
12. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, D'Embden H: Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 16:499-502, 1993
13. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
14. Bavenholm PN, Kuhl J, Pigon J, Saha AK, Ruderman NB, Efendic S: Insulin resistance in type 2 diabetes: association with truncal obesity, impaired fitness, and atypical malonyl coenzyme A regulation. J Clin Endocrinol Metab 88:82-87, 2003
15. Astrand PO, Rodahl K: Textbook of Work Physiology. 3rd ed. Singapore, McGraw-Hill, 1986
16. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377-381, 1982
17. American Diabetes Association: Clinical practice recommendations 2005. Diabetes Care 28 (Suppl. 1):S1-S79, 2005
18. Boule NG, Kenny GP, Haddad E, Wells GA, Sigal RJ: Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. Diabetologia 46:1071-1081, 2003
19. Mourier A, Gautier JF, De Kerviler E, Bigard AX, Villette JM, Garnier JP, Duvallet A, Guezennec CY, Cathelineau G: Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM: effects of branched-chain amino acid supplements. Diabetes Care 20:385-391, 1997
20. American Diabetes Association: Physical activity/exercise and diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S58-S62, 2004
21. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 36:689-692, 1987
22. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367, 1998
23. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
24. Delorme S, Chiasson JL: Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 5:184-189, 2005
25. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA: Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 15:485-491, 1998
26. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
27. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A: Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 28:195-200, 2002
28. Rosenbaum P, Peres RB, Zanella MT, Ferreira SR: Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Braz J Med Biol Res 35:877-884, 2002
29. Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S: Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 55:221-227, 2002
30. Gudbjornsdottir S: Nationella diabetes-registret årsrapport 2005. Diabetolognytt 18 (Suppl. 1):S1-S63, 2005